Complement C4d-specific antibodies for the diagnosis of lung cancer

Oncotarget

Volumn 9, Issue 5, 2018, Pages 6346-6355

  Ajona, Daniel ^a,b   Okrój, Marcin ^c,d   Pajares, María J ^a,e   Agorreta, Jackeline ^a,e   Lozano, María D ^f   Zulueta, Javier J ^f   Verri, Carla ^g   Roz, Luca ^g   Sozzi, Gabriella ^g   Pastorino, Ugo ^g   Massion, Pierre P ^h   Montuenga, Luis M ^a,e   Blom, Anna M ^c   Pio, Ruben ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c LUND UNIVERSITY   (Sweden)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e UNIVERSITY OF NAVARRA   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Biomarker; Complement C4d; Diagnosis; Indeterminate pulmonary nodules; Lung cancer

Indexed keywords

COMPLEMENT COMPONENT C4D; PROTEIN ANTIBODY;

ANTIBODY DETECTION; ARTICLE; ASSAY; ASYMPTOMATIC DISEASE; BENIGN NEOPLASM; BLOOD SAMPLING; BRONCHOALVEOLAR LAVAGE FLUID; CANCER RISK; CANCER SCREENING; CANCER STAGING; CASE CONTROL STUDY; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK POPULATION; HUMAN; LUNG CANCER; LUNG LAVAGE; LUNG NODULE; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

EID: 85040687768     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.23690     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29
2. Palma JF, Das P, Liesenfeld O. Lung cancer screening: utility of molecular applications in conjunction with lowdose computed tomography guidelines. Expert Rev Mol Diagn. 2016; 16:435-47
3. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006; 355:1763-71
4. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365:395-409
5. Veronesi G, Maisonneuve P, Spaggiari L, Rampinelli C, Pardolesi A, Bertolotti R, Filippi N, Bellomi M. Diagnostic performance of low-dose computed tomography screening for lung cancer over five years. J Thorac Oncol. 2014; 9:935-9
6. Sozzi G, Boeri M. Potential biomarkers for lung cancer screening. Transl Lung Cancer Res. 2014; 3:139-48
7. Veronesi G, Bianchi F, Infante M, Alloisio M. The challenge of small lung nodules identified in CT screening: can biomarkers assist diagnosis? Biomark Med. 2016; 10:137-43
8. Montani F, Marzi MJ, Dezi F, Dama E, Carletti RM, Bonizzi G, Bertolotti R, Bellomi M, Rampinelli C, Maisonneuve P, Spaggiari L, Veronesi G, Nicassio F, et al. miR-Test: a blood test for lung cancer early detection. J Natl Cancer Inst. 2015; 107:djv063
9. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, Roz L, Conte D, Grassi M, Sverzellati N, Marchiano A, Negri E, La Vecchia C, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014; 32:768-73
10. Kneip C, Schmidt B, Seegebarth A, Weickmann S, Fleischhacker M, Liebenberg V, Field JK, Dietrich D. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol. 2011; 6:1632-8
11. Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, Parsons E, Mitra N, Brody J, Lenburg ME, Spira A. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med. 2015; 373:243-51
12. Pecot CV, Li M, Zhang XJ, Rajanbabu R, Calitri C, Bungum A, Jett JR, Putnam JB, Callaway-Lane C, Deppen S, Grogan EL, Carbone DP, Worrell JA, et al. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev. 2012; 21:786-92
13. Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, Lee LW, McLean M, Law S, Butler H, Schirm M, Gingras O, Lamontagne J, Allard R, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med. 2013; 5:207ra142
14. Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JF. Audit of the autoantibody test, EarlyCDT(R)-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 2014; 83:51-5
15. Ajona D, Pajares MJ, Corrales L, Perez-Gracia JL, Agorreta J, Lozano MD, Torre W, Massion PP, De-Torres JP, Jantus-Lewintre E, Camps C, Zulueta JJ, Montuenga LM, et al. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst. 2013; 105:1385-93
16. Ajona D, Razquin C, Pastor MD, Pajares MJ, Garcia J, Cardenal F, Fleischhacker M, Lozano MD, Zulueta JJ, Schmidt B, Nadal E, Paz-Ares L, Montuenga LM, et al. Elevated levels of the complement activation product c4d in bronchial fluids for the diagnosis of lung cancer. PLoS One. 2015; 10: e0119878
17. Ajona D, Pajares MJ, Chiara MD, Rodrigo JP, Jantus-Lewintre E, Camps C, Suarez C, Bagan JV, Montuenga LM, Pio R. Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. Oral Dis. 2015; 21:899-904
18. Law SK, Dodds AW. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci. 1997; 6:263-74
19. Blom AM, Osterborg A, Mollnes TE, Okroj M. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol Immunol. 2015; 66:164-70
20. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, Wiener RS. Evaluation of individuals with pulmonary nodules: When is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143
21. Vachani A, Pass HI, Rom WN, Midthun DE, Edell ES, Laviolette M, Li XJ, Fong PY, Hunsucker SW, Hayward C, Mazzone PJ, Madtes DK, Miller YE, et al. Validation of a multiprotein plasma classifier to identify benign lung nodules. J Thorac Oncol. 2015; 10:629-37
22. Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Verderio P, Pastorino U. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst. 2005; 97:1848-50
23. Campbell LD, Betsou F, Garcia DL, Giri JG, Pitt KE, Pugh RS, Sexton KC, Skubitz AP, Somiari SB. Development of the ISBER best practices for repositories: Collection, storage, retrieval and distribution of biological materials for research. biopreserv biobank 2012; 10:232-3
24. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res. 2012; 5:992-1006
25. Sanchez-Salcedo P, Berto J, De-Torres JP, Campo A, Alcaide AB, Bastarrika G, Pueyo JC, Villanueva A, Echeveste JI, Lozano MD, Garcia-Velloso MJ, Seijo LM, García J, et al. Lung cancer screening: fourteen year experience of the Pamplona Early Detection Program (P-IELCAP). Arch Bronconeumol. 2015; 51:169-76
26. Pastorino U, Rossi M, Rosato V, Marchianò A, Sverzellati N, Morosi C, Fabbri A, Galeone C, Negri E, Sozzi G, Pelosi G, La Vecchia C. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012; 21:308-15
27. Pio R, Garcia J, Corrales L, Ajona D, Fleischhacker M, Pajares MJ, Cardenal F, Seijo L, Zulueta JJ, Nadal E, Witt C, Lozano MD, Schmidt B, et al. Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19:2665-72
28. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111:1710-7
29. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004
30. Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013; 56:232-9